Skip to content

The impact of whole meal intervention on Diabetes by using different dietary patterns

The impact of whole meal intervention on Diabetes by using different dietary patterns

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124440
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-05-12
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Full-Meal Intervention Group with Jiangnan Dietary Pattern:Modified Jiangnan dietary pattern recipes were formulated based on China Diabetes Dietary Guidelines and 2023 Dietary Guidelines for Adults w

Sponsors

The Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or above, with no restrictions on gender. 2. Diagnosed with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) by a medical institution, with a fasting blood glucose (FBG) level ranging from 6 to 8 mmol/L or a 2-hour postprandial blood glucose (2h PPG) level ranging from 8 to 10 mmol/L. 3. Currently on a stable hypoglycemic regimen for no less than 60 consecutive days, with no anticipated need for regimen adjustment during the clinical trial period. 4. Able and willing to cooperate with and complete the dietary survey prior to enrollment. 5. Voluntarily participates in the nutritional intervention and signs the written informed consent form for the study.

Exclusion criteria

Exclusion criteria: 1. Patients who are unable to take oral nutrition, or whose oral intake fails to meet their own nutritional requirements, such as those with chewing or swallowing disorders, reduced gastrointestinal motility, etc. 2. Patients with diseases that impair food digestion and absorption, including severe gastrointestinal inflammation, active peptic ulcers, post-gastrointestinal resection status, short bowel syndrome, etc. 3. Patients with comorbid acute or chronic infectious diseases (e.g., tuberculosis, HIV infection, viral hepatitis); those with abnormal liver function (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels exceeding 3 times the upper limit of normal [ULN]); those with renal diseases (serum creatinine levels exceeding the upper limit of normal); and patients with malignant tumors. 4. Patients with hyperuricemia or gout. 5. Patients with psychiatric disorders. 6. Patients who are pregnant or lactating. 7. Patients with communication difficulties that prevent them from completing questionnaires, such as those with speech, hearing or visual impairments, etc. 8. Patients with known allergies to any component of the study intervention diet, or patients with congenital metabolic disorders. 9. Any other circumstances that the investigators deem inappropriate for study participation.

Design outcomes

Primary

MeasureTime frame
Glycated albumin;

Secondary

MeasureTime frame
Glycated hemoglobin;Glucose;16S rRNA of gut microbiota;Body Composition Analysis;

Countries

China

Contacts

Public ContactPianhong Zhang

The Second Affiliated Hospital of Zhejiang University School of Medicine

zrlcyyzx@zju.edu.cn+86 137 5711 9193

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026